

Item 8.01. Other Events.

On June 18, 2018, Immune Design Corp. (the “Company”) commenced a tender offer to exchange eligible stock options for replacement stock options with modified terms, pursuant to the Offer to Exchange Eligible Options for New Options, dated June 18, 2018, as amended (the “Exchange Offer”). The Exchange Offer expired at 6:00 p.m., Pacific Time, on Tuesday, July 17, 2018.

Pursuant to the Exchange Offer, 31 employees elected to exchange outstanding stock options, and the Company accepted for cancellation, stock options to purchase an aggregate of 1,590,083 shares of the Company’s common stock (“Common Stock”), representing approximately 65% of the total shares of Common Stock underlying the stock options eligible for exchange. On July 17, 2018, immediately following the expiration of the Exchange Offer, the Company granted new stock options to purchase 962,099 shares of Common Stock, pursuant to the terms of the Exchange Offer and the Company’s 2014 Omnibus Incentive Plan. The exercise price per share of the stock options granted pursuant to the Exchange Offer was \$4.40 per share, which is the closing price per share of Common Stock on The Nasdaq Global Market on the grant date of the stock options. The vesting terms of the new stock options are described in detail in the Exchange Offer.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNE DESIGN CORP.

By: /s/ Carlos Paya, M.D., Ph.D.
Carlos Paya, M.D., Ph.D.
President and Chief Executive Officer

Dated: July 18, 2018